Betahistine Dosing
Based on the highest quality evidence from the BEMED trial, betahistine dosing for Ménière's disease has been studied at 48 mg/day (low dose: 2 × 24 mg daily) and 144 mg/day (high dose: 3 × 48 mg daily), though neither dose demonstrated superiority over placebo for reducing vertigo attacks. 1
Standard Dosing Regimens
For Ménière's Disease
- Low-dose regimen: 48 mg/day, divided as 24 mg twice daily 1
- High-dose regimen: 144 mg/day, divided as 48 mg three times daily 1
- Traditional lower dosing: 16-24 mg three times daily (48-72 mg/day total) has been used historically 2
The BEMED trial—the most rigorous double-blind RCT conducted over 9 months—found no significant difference between placebo, 48 mg/day, or 144 mg/day betahistine in reducing vertigo attack rates. 1 The American Academy of Otolaryngology-Head and Neck Surgery guideline committee states they are "unable to make a definitive statement on use of betahistine to control MD symptoms" based on this high-quality evidence. 1
For Uncompensated Unilateral Vestibulopathy
- Initial dose: 36 mg/day for 4 weeks 3
- High-dose escalation: 72 mg/day for 4-16 weeks if initial response inadequate 3
A 2024 study demonstrated that 72 mg/day betahistine significantly improved Dizziness Handicap Inventory scores in patients with intractable dizziness from unilateral vestibulopathy, while the standard 36 mg/day dose did not. 3 Long-term administration (16 weeks) at 72 mg/day provided further improvement in responding patients. 3
Duration of Treatment
- Minimum trial period: 2-12 weeks for most conditions 1
- Extended treatment: Up to 9 months has been studied in clinical trials 1
- Long-term prophylaxis: At least 12 months may be considered for Ménière's disease, with higher doses (48 mg three times daily) showing better efficacy than lower doses in open-label studies 2
The guidelines note there are "no clear data to suggest the length of time that these agents should be used for," and recommend discussing titration or discontinuation once symptoms subside. 1
Important Clinical Considerations
Contraindications and Cautions
- Absolute contraindication: Pheochromocytoma 1
- Use with caution: Asthma, history of peptic ulcer disease 1
- Relative contraindications: Renal or cardiac disease (when considering as part of broader treatment strategy) 1
Safety Profile
Betahistine is generally well-tolerated with rare serious side effects. 1 Common adverse effects include headache, balance disorder, nausea, nasopharyngitis, feeling hot, eye irritation, palpitations, and upper gastrointestinal symptoms. 1
Monitoring
Patients should be reassessed "as often as clinically warranted" for symptom improvement, stabilization, medication intolerance, or side effects. 1
Evidence Quality and Clinical Reality
Critical caveat: The 2020 AAO-HNS guideline emphasizes that the BEMED trial represents "the best evidence that we have" and contradicts earlier meta-analyses that favored betahistine. 1 The Cochrane systematic review showed a 56% reduction in vertigo with betahistine versus placebo, but these results "must be interpreted with caution" due to low study quality. 1
Despite lack of definitive efficacy evidence for Ménière's disease, the AAO-HNS guideline offers betahistine as an option for maintenance therapy, acknowledging variable patient responses and the balance of minimal harm against potential benefit. 4 In real-world practice, a trial of betahistine at 48-144 mg/day for 2-3 months is reasonable given its excellent safety profile, with discontinuation if no benefit is observed.
For conditions other than Ménière's disease (such as uncompensated vestibulopathy), emerging evidence supports higher doses (72 mg/day) with longer treatment durations. 3